Yamada S, Bonjour J P, Fleisch H
Acta Endocrinol (Copenh). 1986 Apr;111(4):572-6. doi: 10.1530/acta.0.1110572.
It has been suggested that 1 alpha, 24(R)-dihydroxyvitamin D3 (1,24(OH)2D3), a chemically synthesized vitamin D analogue, may have the property to enhance whole-body Ca retention and may thus be of use in osteoporosis. In order to test this hypothesis the main fluxes of Ca metabolism were measured in vitamin D-replete rats injected ip with 1.24(OH)2D3 at daily doses of 25, 50 and 100 pmol for 10 days. As compared with pair fed control animals, rats treated with 1,24(OH)2D3 displayed a significant rise in net intestinal absorption of Ca and in urinary excretion of Ca, and increase in bone resorption but no significant change in bone formation. Whole body Ca retention was not changed at 25 pmol/day and showed a trend to decrease at 50 and 100 pmol/day. In conclusion these results do not suggest that among available vitamin D analogues, 1,24(OH)2D3 would be particularly useful for increasing bone Ca retention in osteoporosis.
有人提出,1α,24(R)-二羟基维生素D3(1,24(OH)2D3),一种化学合成的维生素D类似物,可能具有增强全身钙潴留的特性,因此可能用于治疗骨质疏松症。为了验证这一假设,对维生素D充足的大鼠腹腔注射1,24(OH)2D3,每日剂量分别为25、50和100皮摩尔,持续10天,测量其钙代谢的主要通量。与配对喂养的对照动物相比,用1,24(OH)2D3治疗的大鼠钙的净肠道吸收和尿钙排泄显著增加,骨吸收增加,但骨形成无显著变化。全身钙潴留量在每天25皮摩尔时没有变化,在每天50和100皮摩尔时有下降趋势。总之,这些结果并不表明在现有的维生素D类似物中,1,24(OH)2D3对增加骨质疏松症患者的骨钙潴留特别有用。